Contents
pdf Download PDF
pdf Download XML
47 Views
14 Downloads
Share this article
Research Article | Volume 12 Issue 3 (None, 2026) | Pages 81 - 85
Comparative Safety and Symptom Outcomes Of Olanzapine And Risperidone In First-Episode Psychosis: A Prospective Observational Hospital-Based Study
 ,
1
Associate Professor And Head Department Of Psychiatry Government Medical College Datia
2
Senior Resident Pharmacology Department Gajra Raja Medical College
Under a Creative Commons license
Open Access
Received
Feb. 15, 2026
Revised
Feb. 27, 2026
Accepted
March 12, 2026
Published
March 28, 2026
Abstract
Background: First-episode psychosis (FEP) requires timely treatment, while antipsychotic-associated adverse effects may influence adherence and longer-term health. Olanzapine and risperidone are commonly used second-generation antipsychotics but have differing tolerability profiles. Objective: To compare symptom change and adverse-effect profiles associated with olanzapine and risperidone in patients with FEP. Material & Methods: This prospective, observational, hospital-based comparative study was conducted in the Psychiatry OPD and IPD of Government Medical College, Datia, Madhya Pradesh, from 1 June 2023 to 31 May 2024. A total of 106 patients aged 18–45 years were included, with 53 receiving olanzapine and 53 receiving risperidone according to the treating psychiatrist’s decision. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline, day 30 and day 90. Clinical and laboratory monitoring included weight, HbA1c, lipid profile, prolactin and other biochemical parameters; adverse events were recorded during follow-up. Results: Both groups showed reductions in positive, negative and general psychopathology scores over 90 days. Between-group comparisons were reported as not statistically significant for the principal symptom domains (p>0.05), although the study narrative described a greater reduction in negative symptoms with olanzapine. Olanzapine was associated with more weight gain (34.0% vs 15.1%; p=0.049) and hyperglycaemia (28.3% vs 5.7%; p=0.004). Risperidone was associated with more extrapyramidal symptoms (26.4% vs 3.8%; p=0.002) and hyperprolactinaemia (15.1% vs 1.9%; p=0.019). Anticholinergic symptoms were more frequent with olanzapine (13.2% vs 1.9%; p=0.033). The lower frequency of extrapyramidal and prolactin-related adverse effects with olanzapine may support better treatment acceptability; however, adherence and dropout were not directly reported. Conclusion: Both medicines were associated with clinical improvement during 90-day follow-up. Olanzapine had fewer reported extrapyramidal and prolactin-related adverse effects, which may favour treatment acceptability and continuity. However, better compliance or lower dropout with olanzapine cannot be concluded from this dataset because adherence and discontinuation outcomes were not reported. Olanzapine also showed greater metabolic liability, whereas risperidone showed more extrapyramidal and prolactin-related effects. Treatment selection should therefore consider individual clinical and metabolic risks, with appropriate monitoring. Numerical inconsistencies in the outcome tables should be resolved against the original dataset before journal submission.
Keywords
INTRODUCTION
Psychosis is a clinical syndrome characterised by disturbances in perception, thought content and behaviour, including hallucinations, delusions and disorganisation. First-episode psychosis refers to the first presentation of psychotic symptoms and is often associated with substantial distress and functional disruption for patients and families. Early recognition and effective treatment are important because the initial episode may influence subsequent clinical course and psychosocial functioning. The pathophysiology of psychosis is complex and involves several neurotransmitter systems. Dopaminergic dysregulation, particularly increased mesolimbic dopamine activity, has an established role in positive psychotic symptoms; glutamatergic, GABAergic and other pathways may also contribute. Second-generation antipsychotics act through combinations of dopamine D2 and serotonin 5-HT2A receptor antagonism, with additional receptor actions contributing to efficacy and tolerability. Olanzapine and risperidone are widely used second-generation antipsychotics. Their clinical benefits must be balanced against different adverse-effect liabilities. Olanzapine is associated with weight gain and metabolic changes, while risperidone is associated with extrapyramidal symptoms and prolactin elevation. These differences are clinically relevant in young people beginning treatment for FEP, where tolerability can affect adherence. The present study compared symptom improvement and adverse drug reactions among patients with FEP treated with olanzapine or risperidone at Government Medical College, Datia, Madhya Pradesh. Aim and objectives The primary aim was to assess and compare the safety profile and symptom remission associated with olanzapine and risperidone in patients with first-episode psychosis. The secondary objectives were to describe sociodemographic characteristics, evaluate adverse-effect profiles, and compare symptom changes during follow-up.
MATERIALS AND METHODS
Study Design and Setting This was a prospective, observational, hospital-based comparative study conducted in the Psychiatry Outpatient and Inpatient Departments of Government Medical College, Datia, Madhya Pradesh, India. The study period was 12 months, from 1 June 2023 to 31 May 2024. Inclusion Criteria: Patients were enrolled based on the following criteria: • All patients with first episode psychosis between the age of 18 to 45 yrs. • Patients diagnosed by psychiatrists according to ICD-11 criteria for first episode psychosis. • Participation was contingent on the willingness of the patient’s legally acceptable relatives (LAR) to provide informed consent. Exclusion Criteria: Patients meeting the following criteria were excluded: • Any ICD-11 diagnosis other than first episode psychosis or the presence of documented medical or neurological diseases. • Utilization of atypical neuroleptics or concomitant therapy such as mood stabilizers or antidepressants, and finally any case with depot antipsychotics. • Patients with a history of substance abuse.
RESULTS
Participant characteristics A total of 106 participants were included, with 53 in each treatment group. The largest age category was 20–35 years (47.2% in the olanzapine group and 50.9% in the risperidone group). The olanzapine group included 28 males (52.8%) and 25 females (47.2%); the risperidone group included 26 males (49.1%) and 27 females (50.9%). Most participants were from rural areas. The reported income and occupation distributions were not significantly different between groups; however, some demographic tables contain percentage or denominator inconsistencies and should be checked against the master chart. Characteristic Olanzapine (n=53) Risperidone (n=53) Age 20–35 years 25 (47.2%) 27 (50.9%) Male 28 (52.8%) 26 (49.1%) Female 25 (47.2%) 27 (50.9%) Rural residence 32 participants 29 participants Change in psychopathology scores Within-group analyses showed significant reductions from baseline to day 30 and day 90 in positive symptoms, negative symptoms and general psychopathology in both treatment groups (reported p=0.000; conventionally presented as p<0.001). The available tables contain conflicting values for some follow-up scores. The inter-group comparison table is reproduced below as the principal comparative summary, but these values require verification against the original statistical output and master chart before publication. Outcome measure Time point Olanzapine (mean ± SD) Risperidone (mean ± SD) General psychopathology Baseline 38.01 ± 2.84 39.24 ± 3.58 General psychopathology Day 30 29.51 ± 2.71 28.92 ± 2.11 General psychopathology Day 90 27.24 ± 4.10 20.82 ± 4.52 Positive profile Baseline 41.60 ± 4.95 40.69 ± 5.59 Positive profile Day 30 26.47 ± 9.58 28.30 ± 7.65 Positive profile Day 90 22.90 ± 8.49 23.37 ± 9.09 Negative profile Baseline 38.52 ± 6.41 38.94 ± 5.94 Negative profile Day 30 25.20 ± 8.76 35.92 ± 11.20 Negative profile Day 90 16.92 ± 7.05 28.92 ± 10.03 The narrative states that no statistically significant between-group differences were found for the principal symptom outcomes (p>0.05), while also describing greater improvement in negative symptoms with olanzapine. Because the tabled negative-profile values and the narrative are not fully concordant, a definitive between-group efficacy claim cannot be made from the text alone. Metabolic and laboratory parameters The report indicates a greater increase in weight and HbA1c with olanzapine, whereas increases in lipid-profile values and prolactin were greater with risperidone. Baseline values were described as comparable. The available summary table reports the following values: Parameter Group Baseline Endpoint Weight (kg) Olanzapine 76.07 ± 1.30 76.26 ± 1.55 Weight (kg) Risperidone 75.28 ± 2.64 75.29 ± 2.84 HbA1c Olanzapine 5.526 ± 0.11 5.903 ± 0.06 HbA1c Risperidone 5.508 ± 0.15 5.520 ± 0.18 Lipid profile* Olanzapine 197.56 ± 5.67 198.22 ± 6.34 Lipid profile* Risperidone 199.03 ± 9.04 201.28 ± 7.60 Prolactin Olanzapine 10.90 ± 0.79 10.97 ± 0.87 Prolactin Risperidone 11.14 ± 1.02 11.96 ± 0.21 Adverse drug events The reported adverse-event frequencies differed between treatment groups. Weight gain and hyperglycaemia were more frequent with olanzapine, whereas extrapyramidal symptoms and hyperprolactinaemia were more frequent with risperidone. Anticholinergic symptoms were also more frequent with olanzapine. Adverse event Olanzapine (n=53) Risperidone (n=53) Reported p-value Weight gain 18 (34.0%) 8 (15.1%) 0.049 Hyperglycaemia 15 (28.3%) 3 (5.7%) 0.004 Sedation 5 (9.4%) 6 (11.3%) 0.93 Extrapyramidal symptoms 2 (3.8%) 14 (26.4%) 0.002 Anticholinergic symptoms 7 (13.2%) 1 (1.9%) 0.033 Hyperprolactinaemia 1 (1.9%) 8 (15.1%) 0.019 Insomnia 1 (1.9%) 6 (11.3%) 0.058 Sexual dysfunction 1 (1.9%) 4 (7.5%) 0.033* Postural hypotension 1 (1.9%) 2 (3.8%) 0.77
DISCUSSION
This prospective observational study compared clinical symptom trajectories and adverse-effect profiles in 106 patients with first-episode psychosis treated with olanzapine or risperidone over 90 days. Both groups demonstrated improvement in positive symptoms, negative symptoms and general psychopathology during follow-up. The findings support the clinical effectiveness of both agents in routine care, although the observational design and inconsistencies between some reported tables limit conclusions about comparative efficacy. The most clinically relevant difference was the pattern of adverse events. Olanzapine was associated with a higher frequency of weight gain and hyperglycaemia and with a greater increase in HbA1c. These observations are consistent with the recognised metabolic liability of olanzapine and support baseline and follow-up monitoring of body weight and glycaemic status. The absolute mean weight change shown in the summary table is small; therefore, the clinical interpretation should rely on verified individual-level data and the study's definition of weight gain. Risperidone was associated with more extrapyramidal symptoms and hyperprolactinaemia. These effects are clinically important because motor symptoms and prolactin-related effects may affect comfort, sexual and reproductive health, and willingness to continue treatment. The lower frequency of these adverse effects in the olanzapine group may contribute to better treatment acceptability. However, this study did not report a direct measure of medication adherence, compliance or treatment discontinuation; consequently, it cannot establish that olanzapine produced better compliance or fewer dropouts. Monitoring should include assessment for movement disorders and symptoms suggestive of prolactin elevation. Anticholinergic symptoms were more frequent in the olanzapine group. Sedation occurred in both groups without a statistically significant difference in the reported comparison. Insomnia was numerically more frequent with risperidone, but the reported p-value (0.058) did not meet the prespecified 0.05 threshold. Taken together, the adverse-effect findings suggest that olanzapine may have an advantage in terms of fewer extrapyramidal and prolactin-related effects, while risperidone may have a more favourable metabolic profile. The choice between the two medicines should therefore be individualised rather than based on symptom response alone. The study has several strengths, including prospective follow-up, inclusion of both OPD and IPD patients, a defined 90-day assessment schedule, and collection of clinical and laboratory safety measures. Important limitations include the single-centre setting, modest sample size, convenience sampling, non-random treatment allocation, short follow-up, and potential confounding by baseline clinical characteristics and prescribing decisions. The manuscript also contains internal discrepancies in certain PANSS values, demographic percentages, adverse-event counts and p-values. These should be reconciled with the original master chart and statistical output before journal submission. In addition, adherence, compliance and treatment-discontinuation data were not presented, so any claim of lower dropout or better compliance with either medicine would require confirmation from the source records. No causal inference can be drawn from this observational comparison.
CONCLUSION
Both olanzapine and risperidone were associated with improvement in psychotic symptoms over 90 days in this hospital-based cohort. Olanzapine was associated with fewer extrapyramidal symptoms and less hyperprolactinaemia, which may provide an advantage in treatment acceptability and willingness to continue therapy. Nevertheless, better compliance or lower dropout with olanzapine was not established because adherence and discontinuation outcomes were not reported. Olanzapine was also associated with more weight gain, hyperglycaemia and anticholinergic symptoms, whereas risperidone was associated with more extrapyramidal symptoms and hyperprolactinaemia. Thus, olanzapine may have a more favourable profile for some aspects of tolerability, but treatment should be individualised and accompanied by regular metabolic, neurological and endocrine monitoring. Comparative efficacy findings should be interpreted cautiously until inconsistencies in the source tables are checked against the original dataset.
REFERENCES
1. National Institute of Mental Health. Understanding Psychosis. Available at: https://www.nimh.nih.gov/health/publications/understanding-psychosis. 2. Calabrese J, Al Khalili Y. Psychosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK546579/. 3. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13. 4. Simon GE, Coleman KJ, Yarborough BJ, et al. Incidence and presentation of first-episode psychosis in a population-based sample. Psychiatr Serv. 2017;68(5):456. 5. Shafti SS, Gilanipoor M. A comparative study between olanzapine and risperidone in the management of schizophrenia. Schizophr Res Treat. 2014;2014:307202. 6. Piparva KG, Buch JG, Chandrani KV. Analysis of adverse drug reactions of atypical antipsychotic drugs in psychiatry OPD. Indian J Psychol Med. 2011;33(2):153. 7. Suresh Kumar PN, Anish PK, Rajmohan V. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian J Psychiatry. 2016;58(3):311. 8. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989;(7):59–67. 9. Soria-Chacartegui P, Villapalos-García G, Zubiaur P, et al. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12:711940. 10. Grinchii D, Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int J Mol Sci. 2020;21(24):9532. 11. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment—pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169–179. 12. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130–140. 13. Martino D, Karnik V, Osland S, et al. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry. 2018;63(11):730–739. 14. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617–622. 15. Montejo ÁL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry. 2015;28(6):418–423.
Recommended Articles
Research Article
A Randomized Observer-Blinded Comparison of Nerve Stimulator-Guided Infraclavicular and Supraclavicular Brachial Plexus Blocks for Upper Limb Surgery
...
Published: 31/10/2026
Research Article
Clinical Efficacy, Safety and Postoperative Outcomes of Thermal Balloon Endometrial Ablation for Abnormal Uterine Bleeding: A Retrospective Study of 14 Cases
...
Published: 19/11/2026
Original Article
Comparison of Dexmedetomidine and Esmolol for Controlled Hypotension and Surgical-Field Quality During Functional Endoscopic Sinus Surgery (FESS)
...
Published: 18/11/2026
Research Article
Awareness and Practices Regarding Forensic OdontologyAmong Dental Practitioners: ACross-Sectional Survey
Published: 20/03/2026
Chat on WhatsApp
© Copyright Journal of Contemporary Clinical Practice